Tharimmune, Inc. (THAR)

NASDAQ: THAR · Real-Time Price · USD
4.770
-0.430 (-8.27%)
At close: Sep 3, 2025, 4:00 PM
4.720
-0.050 (-1.05%)
Pre-market: Sep 4, 2025, 8:37 AM EDT
-8.27%
Market Cap22.11M
Revenue (ttm)n/a
Net Income (ttm)-12.01M
Shares Out 4.64M
EPS (ttm)-5.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,291,538
Open5.120
Previous Close5.200
Day's Range4.540 - 5.230
52-Week Range0.952 - 9.080
Beta1.19
AnalystsStrong Buy
Price Target17.00 (+256.39%)
Earnings DateAug 14, 2025

About THAR

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a resea... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 12, 2022
Employees 3
Stock Exchange NASDAQ
Ticker Symbol THAR
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for THAR stock is "Strong Buy" and the 12-month stock price target is $17.0.

Price Target
$17.0
(256.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic...

15 days ago - Accesswire

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative the...

22 days ago - Accesswire

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic ...

4 weeks ago - Accesswire

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

-Company closes approximately $5.47 million in equity financing in 2Q/3Q25 -TH104 potentially fills a critical National Security Need against Weaponized Fentanyl - TH023 may fulfill the promise of del...

4 weeks ago - Accesswire

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapie...

6 weeks ago - Accesswire

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and...

2 months ago - Accesswire

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative th...

4 months ago - Accesswire

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeuti...

4 months ago - Accesswire

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

BRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therape...

4 months ago - Accesswire

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

BRIDGEWATER, NJ / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therape...

4 months ago - Accesswire

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the ap...

5 months ago - Accesswire

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...

5 months ago - Accesswire

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway -Company leveraging existing human pharmacokinetic data with TH104 -Advancing CMC plan to meet requirements of ...

5 months ago - Accesswire

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda...

5 months ago - Accesswire

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...

6 months ago - Accesswire

Tharimmune to Present at the Microcap Conference 2025

BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immun...

7 months ago - Accesswire

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunolog...

9 months ago - Accesswire

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology...

9 months ago - Accesswire

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in pr...

10 months ago - Accesswire

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...

10 months ago - Accesswire

Tharimmune Announces Upcoming Conference Presentations

BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidate...

10 months ago - Accesswire

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidate...

11 months ago - Accesswire

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile TH104 was well tolerated with no unexpecte...

11 months ago - Accesswire

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - ...

1 year ago - Accesswire

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of ther...

1 year ago - Accesswire